Acalabrutinib, marketed as Calquence, has received FDA approval for specific indications related to certain types of lymphoma and leukemia.
When Was Acalabrutinib First Approved by the FDA?
The U.S. Food and Drug Administration (FDA) initially approved acalabrutinib in October 2017 as a treatment for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [1].
What Other Cancers Can Acalabrutinib Treat?
Following its initial approval, the FDA expanded the indications for acalabrutinib. In November 2019, it was approved for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy [1]. Subsequently, in June 2020, the drug gained approval for adult patients with CLL or SLL regardless of prior therapy, making it a first-line treatment option [1].
How Does Acalabrutinib Work?
Acalabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. BTK is a protein found in B cells, a type of white blood cell, that plays a crucial role in cell signaling pathways essential for B-cell development, proliferation, and survival [2]. By inhibiting BTK, acalabrutinib disrupts these pathways, thereby reducing the growth and spread of cancerous B cells [2].
What Are the Potential Side Effects of Acalabrutinib?
Common side effects associated with acalabrutinib treatment can include diarrhea, fatigue, muscle pain, bruising, and headache [2]. More serious side effects may occur, such as infections, low blood cell counts, bleeding events, heart rhythm abnormalities (atrial fibrillation or atrial flutter), and secondary cancers [2]. Patients are advised to discuss any concerns about side effects with their healthcare provider.
Are There Any Restrictions on Acalabrutinib Use?
The FDA approval for acalabrutinib specifies its use for adult patients diagnosed with specific forms of B-cell malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia or small lymphocytic lymphoma, with particular guidelines for first-line treatment versus treatment after prior therapies [1].
Where Can I Find More Information on Drug Approvals and Patents?
For detailed information on drug approvals, exclusivity periods, and patent data, resources like DrugPatentWatch.com can provide comprehensive insights [3].